The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.z

Progression, acceleration or exacerbation of preexisting ILD/fibrosis

Publications

Wendling D, Vidon C, Godfrin-Valnet M, Rival G, Guillot X, Prati C

Exacerbation of combined pulmonary fibrosis and emphysema syndrome during tocilizumab therapy for rheumatoid arthritis.

Joint, bone, spine : revue du rhumatisme 2013 Dec;80;670-1 — 2013 Dec — 670-1

Kawashiri SY, Kawakami A, Sakamoto N, Ishimatsu Y, Eguchi K

A fatal case of acute exacerbation of interstitial lung disease in a patient with rheumatoid arthritis during treatment with tocilizumab.

Rheumatology international 2012 Dec;32;4023-6 — 2012 Dec — 4023-6